BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.08B
• Dividend Yield: N/A
• Average Volume (3M): 363.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -18.82%
• EPS Growth: 92.56%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 48,148,045
• 10 Day Avg. Volume: 392,925
• 30 Day Avg. Volume: 363,004
• PEG Ratio: 0.83
• Price to Book (P/B): 3.43
• Price to Sales (P/S): 14.54
• P/FCF Ratio: 229.80
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 14.74
• Enterprise Value/Gross Profit: 18.41
• Enterprise Value/Ebitda: -223.96
• 1Y Price Target: $33.20
• Price Target Upside: 45.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $22.00 ▼(-3.68% Downside)

BioLife Solutions' overall stock score reflects a mix of positive and negative factors. The most significant strength is the strong revenue growth and improved profitability highlighted in the recent earnings call, which suggests potential for future growth. However, financial performance challenges, including declining revenues and profitability, weigh heavily on the score. Technical indicators suggest a bearish trend, and valuation metrics indicate overvaluation. The absence of a dividend yield further impacts the valuation score.

Positive Factors

Revenue Growth

Strong revenue growth in cell processing indicates robust demand and market expansion, supporting long-term business sustainability.

Market Leadership

Dominant market position in cell and gene therapy trials enhances competitive advantage and potential for future growth.

Strategic Focus

Divesting non-core assets allows focus on core competencies, strengthening financial position and supporting strategic growth.

Negative Factors

Declining Gross Margin

Declining gross margins can pressure profitability, indicating potential challenges in cost management and pricing strategy.

Increased Operating Expenses

Rising operating expenses may strain profitability and cash flow, requiring efficiency improvements to sustain long-term growth.

Negative Profitability

Ongoing losses and negative profitability metrics highlight operational challenges, impacting financial health and investor confidence.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation products, which include cryopreservation media, storage containers, and automated thawing systems. The company also earns income from its proprietary technology licenses and research collaborations with pharmaceutical and biotechnology companies. Key revenue streams include direct product sales, partnerships with major players in the cell and gene therapy sectors, and ongoing contracts with research institutions. Significant partnerships with industry leaders enhance BioLife's market presence and contribute to its earnings by expanding its customer base and driving product adoption in various therapeutic applications.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions faces challenges with declining revenues and profitability, as evidenced by negative net profit margins and ROE. Despite these issues, the company maintains a strong gross profit margin and a conservative leverage position. Cash flow generation is moderate, but the decline in free cash flow growth is a concern. Overall, the company needs to address its profitability and revenue growth to improve its financial health.

Income Statement

BioLife Solutions has experienced declining revenue over the TTM period, with a negative revenue growth rate of -3.27%. The company shows a strong gross profit margin of 81.42%, indicating efficient cost management. However, the net profit margin is negative at -7.23%, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, suggesting operational challenges.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.069, indicating conservative leverage. However, the return on equity is negative at -1.61%, highlighting profitability issues. The equity ratio is relatively stable, suggesting a solid capital structure despite the negative ROE.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth of -7.74% over the TTM period. The operating cash flow to net income ratio is 0.55, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is 0.74, showing some ability to convert earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.00M	82.25M	143.27M	76.24M	119.16M	48.09M
Gross Profit	59.27M	53.67M	46.75M	53.82M	37.75M	27.44M
EBITDA	-4.87M	1.53M	-45.24M	-124.18M	-16.65M	1.48M
Net Income	-3.21M	-20.18M	-66.43M	-139.81M	-8.91M	2.67M
Balance Sheet
Total Assets	392.08M	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	78.95M	104.58M	44.18M	62.70M	69.87M	90.46M
Total Debt	20.68M	30.17M	33.83M	43.71M	26.88M	11.15M
Total Liabilities	38.34M	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	353.74M	348.91M	337.66M	364.19M	480.75M	205.25M
Cash Flow
Free Cash Flow	10.56M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	16.84M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	961.00K	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-4.09M	-6.78M	10.59M	16.32M	-2.78M	102.08M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Negative. The current price of 22.84 is below the 20-day moving average (MA) of 24.31, below the 50-day MA of 24.88, and below the 200-day MA of 24.30, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 11.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AZTA	59 Neutral	$1.73B	-30.15	1.41%	―	-9.49%	58.97%
KMTS	52 Neutral	$1.46B	-9.33	-136.96%	―	62.06%	-41.97%
BLFS	52 Neutral	$1.08B	-332.46	-5.20%	―	-18.82%	92.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	46 Neutral	$897.34M	-9.27	-24.65%	―	-32.42%	-540.37%
PLSE	46 Neutral	$929.09M	-12.37	-86.99%	―	―	-40.63%
SMTI	42 Neutral	$197.03M	-4.73	-27.19%	―	30.55%	-340.19%

BioLife Solutions Corporate Events

BioLife Solutions announces planned retirement of key executive

On January 8, 2026, BioLife Solutions, Inc. announced that its Chief Quality and Operations Officer, Karen Foster, will retire from her role effective March 31, 2026. The company emphasized that her retirement is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for her contributions, suggesting a planned leadership transition with no indicated disruption to ongoing business activities.

The most recent analyst rating on (BLFS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.

BioLife Solutions Highlights Financial Performance in Presentation

On November 17, 2025, BioLife Solutions released an investor presentation highlighting its financial performance and strategic focus. The company reported a revenue guidance of $95-96 million for fiscal year 2025, with an expected organic revenue growth of 27-29%. BioLife Solutions has successfully refocused its portfolio by divesting non-core assets and targeting acquisitions, which has led to improved profitability and sustainable growth. The presentation also emphasized the company’s involvement in over 950 active global cell-based therapy trials, underscoring its strong market positioning and commitment to innovation in the cell-based therapy industry.

The most recent analyst rating on (BLFS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.